Patrys has released its Annual Report for the 2023-2024 Financial Year (FY24).
Highlights include:
- Data from preclinical studies with PAT-DX1 and PAT-DX3 presented at US brain cancer conference
- GMP production run of PAT-DX1 completed
- Master Cell Bank (MCB) for PAT‑DX3 characterised and validated, and an integration manufacturing run successfully completed
- Positive preclinical data demonstrating the use of deoxymabs to arrest NETosis and treat vasculitis, and potentially other autoimmune diseases, presented at international meetings